Literature DB >> 2543336

An attempt to reduce the photosensitizing potential of chlorpromazine with the simultaneous use of beta- and dimethyl-beta-cyclodextrins in guinea pigs.

T Hoshino1, K Ishida, T Irie, K Uekama, T Ono.   

Abstract

The effects of topically applied beta-cyclodextrin (beta-CyD) and heptakis(2,6-di-O-methyl)-beta-cyclodextrin (DM-beta-CyD) on photoallergic contact dermatitis due to chlorpromazine hydrochloride (CPZ) were investigated using the photomaximization technique in guinea pigs. From the gross and histological observations, the photosensitizing potential of CPZ with the simultaneous topical use of beta-CyDs was significantly lower than that of CPZ alone. The alleviating efficacy of DM-beta-CyD was greater than that of beta-CyD. beta-CyDs suppressed the penetration of CPZ into the skin through the formation of poorly skin-permeable complexes. In addition, beta-CyDs inhibited (a) the photoinduced free radicals derived from CPZ in the isolated dry skin and (b) the in vitro photochemical binding of CPZ to bovine serum albumin. These observations suggest that beta-CyDs suppress the photochemical reactions between CPZ and biological macromolecules present in the skin, resulting in the failure to form a photoantigen. The present results indicate that DM-beta-CyD is particularly effective in alleviating photoallergic contact dermatitis due to CPZ.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543336     DOI: 10.1007/bf00424275

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  13 in total

1.  Inclusion complexes of beta-cyclodextrin with tranquilizing drugs phenothiazines in aqueous solution.

Authors:  M Otagiri; K Uekama; K Ikeda
Journal:  Chem Pharm Bull (Tokyo)       Date:  1975-01       Impact factor: 1.645

2.  Photoallergic responses to chemicals.

Authors:  I E Kochevar
Journal:  Photochem Photobiol       Date:  1979-10       Impact factor: 3.421

3.  Photochemical binding of photoallergens to human serum albumin: a simple in vitro method for screening potential photoallergens.

Authors:  M D Barratt; K R Brown
Journal:  Toxicol Lett       Date:  1985-01       Impact factor: 4.372

4.  [A new method for the local irritation test. II. Skin irritation test for powder drugs (author's transl)].

Authors:  K Fukawa; Y Ito; S Ohbayashi; K Iwadate; O Irino; T Sawabe
Journal:  Yakugaku Zasshi       Date:  1982-01       Impact factor: 0.302

5.  Photoallergic contact dermatitis in guinea pigs: improved induction technique using Freund's complete adjuvant.

Authors:  H Ichikawa; R B Armstrong; L C Harber
Journal:  J Invest Dermatol       Date:  1981-06       Impact factor: 8.551

6.  Pigmentation due to phenothiazines in high and prolonged dosage.

Authors:  A Satanove
Journal:  JAMA       Date:  1965-01-25       Impact factor: 56.272

7.  Effects of cyclodextrins on chlorpromazine-induced haemolysis and central nervous system responses.

Authors:  K Uekama; T Irie; M Sunada; M Otagiri; K Iwasaki; Y Okano; T Miyata; Y Kasé
Journal:  J Pharm Pharmacol       Date:  1981-11       Impact factor: 3.765

8.  Photocontact urticaria from chlorpromazine.

Authors:  C R Lovell; E Cronin; E L Rhodes
Journal:  Contact Dermatitis       Date:  1986-05       Impact factor: 6.600

Review 9.  Cyclodextrins in drug carrier systems.

Authors:  K Uekama; M Otagiri
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1987       Impact factor: 4.889

10.  Photoinduced free radicals from chlorpromazine and related phenothiazines: relationship to phenothiazine-induced photosensitization.

Authors:  C F Chignell; A G Motten; G R Buettner
Journal:  Environ Health Perspect       Date:  1985-12       Impact factor: 9.031

View more
  1 in total

1.  Enhancement of the antiinflammatory effect of ethyl 4-biphenylyl acetate in ointment by beta-cyclodextrin derivatives: increased absorption and localized activation of the prodrug in rats.

Authors:  H Arima; H Adachi; T Irie; K Uekama; J Pitha
Journal:  Pharm Res       Date:  1990-11       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.